Impact of Biophoton Generator on Chronic-Stroke Patients' Recovery

Each of all participants assigned to the Control or Treatment Group will be continually treated with the current standard of care (SOC), if any. The Control group will use the coded placebo devices, and the Treatment Group will use the coded treatment product. All coded products will be packed with the same container with the same size and weight. Each participant will use the Treatment or Control device at least for 8-hours every day for 4-weeks during sleep and any daytime during the day. Each participant and caregiver will be guided by the study physician to use Katz Index of Independence in Activities of Daily Living (ADL) to measure the level of life independence. The study physician will perform neurological examination. Stroke Impact Scale (SIS) for stroke-specific health status measurement, SF-36 questionnaires (SF-36) to measure life quality, Electroencephalography (EEG) test, and Bio-Well energy test, will be conducted respectively at the baseline, 2 or 4 weeks after the study treatment. SIS and SF-36 questionnaires will be recalled 4 weeks before the baseline for each participant.

Outcome Variables

• Primary Outcome Measure: Regain Life Independence by Normalizing Activities of Daily Living (ADL). Life Independence is defined as the normalization of activities of daily living (ADL), at which time the participant's total ADL score will be increased at least to 4 from the baseline score of 2 or less. The participant, the caregiver, together with a study physician can make the judgment if she/he can independently perform the daily activity at any time during the study period.

• Secondary Outcome Measure:

• Neurological Examination by a Study Physician. [Time Frame: 0-2 weeks, 0-4 weeks after starting the study treatment].
• Stroke Impact Scale (SIS). [Time Frame: 0-2 weeks, 0-4 weeks after starting the study treatment]. The SIS is a stroke-specific, self-report, health status measure. It was designed to assess multidimensional stroke outcomes, including strength, hand function, mobility, communication, emotion, memory and thinking, and participation.
• Brain function change is detected by using an FDA-cleared EEG machine.
• Short Form Health Survey (SF-36) [Time Frame: 0-2 weeks, 0-4 weeks after starting the study treatment] to measure the quality of life as influenced by the investigational medical device (an OTC device). SF-36 has been used worldwide as a standard clinical research tool for many years.
• Energy Level of the Brain. The brain and the other organs, and meridians of the participants will be measured by using Bio-Well GDV Camera device and calculated by multiplication of area on average intensity on correction coefficient. [Time Frame: 0-2 weeks, 0-4 weeks after starting the study treatment].

Safety Outcome: Occurrence of adverse events (AE). Any AE was reported by participants and caregiver. [Time Frame: Any AE occurred at the baseline, at 2-weeks and then at 4-weeks.] Any reported AE will be tabulated and compared between the two groups.

Inclusion criteria

• Must be 18-years or older and can live in a hotel
• Must have a caregiver willing to support the participant's full involvement in the study and can assist to complete all study questionnaires
• Can provide informed consent (maybe assisted by Caregiver)
• Has evidence of a clinical diagnosis of stroke occurred at least 6 months ago.
• Has a disability unable to be living independently per Caregiver
• Can complete all study procedures during the study
• Must be fluent in English (or the Caregiver can fully translate)

Exclusion criteria

• Untreated psychiatric disturbances that would affect trial participation as judged by the Caregiver or by the clinical study medical professional
• Who relies on ventilators
• Co-morbid conditions that would interfere with study activities or response to treatment, which may include severe chronic pulmonary disease, history of uncontrolled seizures, acute or chronic infectious illness, kidney failure, etc.
• Is participating in another investigational drug or device trial.